The report continues “the analysis evaluated 95 confirmed Covid-19 infections among the trial’s 30,000 participants. Moderna, which developed its vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, said 90 cases of Covid-19 were observed in the placebo group versus 5 cases observed in the group that received its two-dose vaccine. That resulted in an estimated vaccine efficacy of 94.5%, it said.”
Shares of the company jumped by more than 11% in premarket trading.
Ivanka Trump tweeted in response to the news “The Moderna/ NIH vaccine is the 2nd candidate in a week to show strong efficacy in Phase 3 trials!”
The Moderna/ NIH vaccine is the 2nd candidate in a week to show strong efficacy in Phase 3 trials!
Congratulations Moderna, @realDonaldTrump, the #OperationWarpSpeed team and all that made this historic breakthrough possible — it will help bring an end to this terrible pandemic! https://t.co/9S7ZH29nbL
— Ivanka Trump (@IvankaTrump) November 16, 2020
Kayleigh McEnany tweeted in responde to the news “Thanks to President @realDonaldTrump’s highly successful Operation Warp Speed, a second vaccine (Moderna) has shown high efficacy in Phase 3 clinical trial.”
She added “This news comes just after Pfizer likewise proved successful. Big wins for all!!”